Evolent Health (NYSE: EVH - Get Free Report) is one of 93 publicly-traded companies in the "Healthcare Technology" industry, but how does it compare to its rivals? We will compare Evolent Health to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends. Profitability This table compares Evolent
Evolent Health, Inc. ( EVH ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Seth Blackley - Co-Founder, CEO & Director Mario Ramos - Chief Financial Officer Conference Call Participants Zachary Haggerty - KeyBanc Capital Markets Inc., Research Division Richard Close - Canaccord Genuity Corp., Research Division Jailendra Singh - Truist Securities, Inc., Research Division Dustin Scaringe - William Blair & Company L.L.C., Research Division Kevin Meli - RBC Capital Markets, Research Division Sahil Veeramoney - Piper Sandler & Co., Research Division Matthew Shea - Needham & Company, LLC, Research Division David Larsen - BTIG, LLC, Research Division Presentation Operator Good morning, and welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2026.
Evolent Health NYSE: EVH raised the lower end of its 2026 adjusted earnings outlook after third-quarter revenue and profitability improved from the preceding quarter, helped by growth in its Performance Suite business and favorable claims development.
Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
WASHINGTON, Nov. 5, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us.
Evolent Health (NYSE: EVH - Get Free Report) and CareCloud (NASDAQ: CCLD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Valuation and Earnings This table compares Evolent Health
WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, before market open, with a conference call to follow at 8:30 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Evolent Health, Inc (NYSE: EVH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eleven have assigned a buy recommendation to the
TransPerfect expands its Evolent partnership to provide enterprise-wide telephonic interpretation and strengthen language access for health plan members.